$95.93
▲ +$1.63
(+1.73%)
Vol 1.2M
13
Quality Score
ok
Deep Check
2/5
ok
Rev ✓
NI ✓
>IPO ✗
Mkt Cap
$19.4B
P/E
16.3
ROE
29.8%
Margin
24.7%
D/E
0.76
Beta
0.82
52W
$54–$109
Wall Street Consensus
33 analysts · Apr 20268
Strong Buy
8
Buy
16
Hold
1
Sell
0
Strong Sell
48.5%
Buy Rating
Price Chart
Similar Stocks
BIIB
Biogen Inc
P/E 16.0
$25.8B
UTHR
United Therapeutics Corp
P/E 16.5
$21.0B
RVMD
Revolution Medicines Inc
$15.4B
MRNA
Moderna Inc
$11.5B
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33.0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
EXEL
Exelixis Inc
P/E 17.3
$11.8B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $1.97 | $1.80 | $-0.17 |
| Sep 2025 | $1.69 | $2.26 | +$0.57 |
| Jun 2025 | $1.50 | $1.57 | +$0.07 |
| Mar 2025 | $1.04 | $1.16 | +$0.12 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 24.1% | 24.1% | 24.1% | 24.1% | 29.8% | 29.8% |
| P/E (TTM) | 15.14 | 19.33 | 19.44 | 21.07 | 16.76 | 16.31 |
| Net Margin | 33.3% | 19.0% | 19.0% | 19.0% | 24.7% | 24.7% |
| Gross Margin | 94.0% | 93.4% | 93.4% | 93.4% | 93.5% | 93.5% |
| D/E Ratio | 0.87 | 0.87 | 0.87 | 0.87 | 0.76 | 0.76 |
| Current Ratio | 2.85 | 2.85 | 2.85 | 2.85 | 3.20 | 3.20 |
Key Ratios
ROA (TTM)
20.4%
P/S (TTM)
4.03
P/B
3.9
EPS (TTM)
$5.91
CF/Share
$2.23
Rev Growth 3Y
+12.4%
52W High
$109.28
52W Low
$53.56
$53.56
52-Week Range
$109.28
How does INCY compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
INCY valuation vs Biotechnology peers
P/E ratio
16.3
▼
13%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4.0
▼
69%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.9
▲
57%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
INCY profitability vs Biotechnology peers
ROE
29.8%
▲
144%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
24.7%
▲
109%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
93.5%
▲
19%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
20.4%
▲
144%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
INCY financial health vs Biotechnology peers
D/E ratio
0.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
3.2
▼
28%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.8
▼
15%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
INCY fundamentals radar
INCY
Peer median
Industry
INCY profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
INCY vs peers: key metrics
Related Signals
Latest AI Opinion
Grok
SKIP
Price action shows a clear downtrend over the past several weeks, with closes dropping from 108.92 on 2026-02-09 to 91.77 currently, breaking below key support around 97-100, and low volume on the latest bar suggesting lack of buying interest, making …
Mar 23, 2026Latest News
No related news yet